

**In the Claims:**

1-44. (Cancelled)

45. (Previously presented) A recombinant or synthetic peptide consisting of the sequence:

$X_1 X_2 X_3$

wherein  $X_1$  and  $X_3$  may be the same or different and each is an amino acid sequence consisting of from 0 to 40 naturally occurring amino acid residues;  $X_2$  has the sequence of FFYTPKTRREAED (SEQ ID NO: 1) and wherein said peptide is capable of reacting with T cells and modifying T-cell function when incubated with cells from subjects having pre-clinical or clinical IDDM.

46. (Previously presented) A recombinant or synthetic peptide consisting of the sequence:

$X_1 X_2 X_3$

wherein  $X_1$  and  $X_3$  may be the same or different and each is an amino acid sequence consisting of from 0 to 40 naturally occurring amino acid residues;  $X_2$  has the sequence of FWYIPPSLRTLED (SEQ ID NO: 2) and wherein said peptide is capable of reacting with T cells and modifying T-cell function when incubated with cells from subjects having pre-clinical or clinical IDDM.

47. (New) The peptide of Claim 45 wherein said peptide is a single chain peptide.

48. (New) The peptide of Claim 45, wherein neither  $X_1$  nor  $X_3$  comprises an arginine residue.

49. (New) The peptide of Claim 45, wherein either  $X_1$  or  $X_3$  comprises more than one arginine residue.

50. (New) The peptide of Claim 45, wherein both  $X_1$  and  $X_3$  comprise at least one arginine residue.